Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

NCT00954915 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Injection site reaction met protocol-defined stopping criteria.

Conditions

Psoriasis

Interventions

BIOLOGICAL: teplizumab

Sponsor

MacroGenics

Collaborators

[object Object]